Krystal Biotech, Inc. (NASDAQ:KRYS) Holdings Reduced by Russell Investments Group Ltd.

Russell Investments Group Ltd. lowered its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 34.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,479 shares of the company's stock after selling 13,219 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.09% of Krystal Biotech worth $3,161,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of KRYS. China Universal Asset Management Co. Ltd. raised its holdings in Krystal Biotech by 111.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company's stock worth $83,000 after purchasing an additional 379 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Krystal Biotech during the third quarter worth $219,000. Prime Capital Investment Advisors LLC purchased a new position in Krystal Biotech during the 4th quarter worth $310,000. Graham Capital Management L.P. purchased a new stake in Krystal Biotech in the third quarter valued at about $330,000. Finally, Confluence Wealth Services Inc. grew its stake in shares of Krystal Biotech by 20.7% during the third quarter. Confluence Wealth Services Inc. now owns 2,920 shares of the company's stock worth $339,000 after acquiring an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 8,087 shares of the business's stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the sale, the chief accounting officer now directly owns 12,556 shares in the company, valued at $1,719,041.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Kathryn Romano sold 8,087 shares of the company's stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the sale, the chief accounting officer now owns 12,556 shares of the company's stock, valued at $1,719,041.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now owns 1,550,882 shares of the company's stock, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold a total of 38,087 shares of company stock valued at $6,210,591 over the last quarter. 14.10% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded up $0.06 during midday trading on Monday, reaching $154.82. 192,160 shares of the company's stock traded hands, compared to its average volume of 358,305. The company has a market cap of $4.42 billion, a P/E ratio of 82.79 and a beta of 0.91. The company has a fifty day simple moving average of $168.49 and a two-hundred day simple moving average of $135.00. Krystal Biotech, Inc. has a 1 year low of $86.03 and a 1 year high of $189.97.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.20 by ($0.17). The business had revenue of $45.25 million for the quarter, compared to the consensus estimate of $47.37 million. The company's revenue was up 452400.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.76) EPS. As a group, research analysts forecast that Krystal Biotech, Inc. will post 2.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on KRYS shares. William Blair reaffirmed an "outperform" rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Citigroup raised their target price on Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Stifel Nicolaus reiterated a "buy" rating and set a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. HC Wainwright restated a "buy" rating and issued a $200.00 price objective on shares of Krystal Biotech in a research note on Monday, May 6th. Finally, Guggenheim increased their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and an average price target of $171.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).